Integrum announces the appointment of Scott Flora as adjunct board membe
Mölndal, Sweden – May 11, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that Scott Flora has been appointed as an adjunct board member effective immediately. Scott Flora brings vast and extensive competence to the company as Integrum is reinforcing the company’s position as a leader of osseointegrated implant systems.
Scott Flora has over 40 years of experience in strategic and leadership roles in the healthcare sector, particularly in surgical devices, and has held prominent leadership positions at companies including Covidien and Smith & Nephew. He is currently Chairman of the Board at Palliare Ltd and a board member at CytoVeris and New View Surgical. Scott Flora also serves as Strategic Advisor to CareSyntax, MiCarePath, and Integrum. He has previously held several leading positions roles as President and CEO of Invuity (acquired by Stryker), Executive Director of Conventus Orthopaedics, President and CEO of OmniGuide Surgical, President of Covidien's Surgical Device Group, President of Smith& Nephew Orthopedic Reconstruction and General Manager at Smith&Nephew Trauma. Scott Flora has also served on the company boards of Invuity (acquired by Stryker), MAKO Surgical, and Tengion.
“We are excited to have Scott Flora joining our Board as an adjunct board member, prolonging his commitment to the company from his current role as a Strategic advisor. He brings valuable strategic knowledge to the company in eventful times as we are expanding our business around the globe,” said Bengt Sjöholm, chairman of the board at Integrum.
“Integrum is well positioned and has a unique offer driving the innovation of osseointegrated implant systems. I am thrilled to take a seat on the board and hope to bring strategic insights that help strengthen the company´s commercial strategy and grow the market,” said Scott Flora, adjunct board member of Integrum.
For more information please contact:
Rickard Brånemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se
Bengt Sjöholm, Chairman of the Board
Phone: + 46 705 313811
E-mail: bengt.sjoholm@bsjab.se
Certified Adviser
Erik Penser Bank is Certified Adviser
ABOUT INTEGRUM
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.